CD40 and atherosclerosis: Although it is currently unknown if this cell type-specific ASO-mediated targeting of CD40 improves atherosclerosis, these data suggest that liposome-mediated delivery of CD40 ASO has the potential to inhibit CD40-driven inflammation in specific immune cell populations without compromising CD40-mediated B cell immune responses.